GARASONE OPHTHALMIC AND OTIC SOLUTION 3 MG
GENTAMICIN (GENTAMICIN SULFATE) : 3 MG BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) : 1 MG · DIN 00682217 · MERCK CANADA INC
Health Canada status: CANCELLED POST MARKET
What is GARASONE OPHTHALMIC AND OTIC SOLUTION?
GARASONE OPHTHALMIC AND OTIC SOLUTION 3 MG contains GENTAMICIN (GENTAMICIN SULFATE) : 3 MG BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 00682217, held by MERCK CANADA INC, supplied as SOLUTION for OPHTHALMIC ; OTIC administration. Health Canada currently lists it as cancelled post market, status dated 01-Apr-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is GARASONE OPHTHALMIC AND OTIC SOLUTION used for?
GARASONE Ophthalmic/Otic Solution and GARASONE Ophthalmic Ointment are indicated for ocular inflammation when concurrent use of an antimicrobial is judged necessary, e.g. staphylococcal blepharoconjunctivitis. GARASONE is indicated for the treatment of non-purulent bacterial infections of the anterior segment of the eye due to organisms sensitive to the antibiotic and when the anti-inflammatory action of betamethasone sodium phosphate is indicated, as in allergic vernal and phlyctenular conjunctivitis; non-purulent blepharitis; interstitial sclerosing post- operative keratitis; superficial chemical and thermal burns of the cornea. GARASONE Ophthalmic/Otic Solution may also be used for the treatment of lesions in the external ear canal, such as acute otitis externa, eczematoid-dermatitis, seborrheic dermatitis and contact dermatitis secondarily infected with susceptible organisms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00682217 |
|---|---|
| Brand name | GARASONE OPHTHALMIC AND OTIC SOLUTION |
| Generic / active ingredient | GENTAMICIN (GENTAMICIN SULFATE) : 3 MG BETAMETHASONE (BETAMETHASONE SODIUM PHOSPHATE) : 1 MG |
| Manufacturer | MERCK CANADA INC |
| Strength | 3 MG |
| Dosage form | SOLUTION |
| Route of administration | OPHTHALMIC ; OTIC |
| Schedule | Prescription |
| ATC code | S03CA06 BETAMETHASONE AND ANTIINFECTIVES |
| AHFS class | 52:08.08 ; 52:04.04 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 01-Apr-2014 |
| Original market date | 1987-12-31 00:00:00 |
How is it administered?
Ophthalmic: 2 drops 3-4 times daily (solution) or thin film 3-4 times daily (ointment). Otic: 3-4 drops 3 times daily. Reassess otic use after 5-7 days.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15 and 30°C, away from light. Store between 15 and 30°C.
How is it supplied?
GARASONE Ophthalmic /Otic Solution - 7.5 mL dropper bottle, GARASONE Ophthalmic Ointment - 3.5 gram tube
Contraindications
Hypersensitivity to components; viral (herpes simplex), mycobacterial, or fungal infections of the eye/ear; perforated tympanic membranes (otic use); after corneal foreign body removal.
Warnings and precautions
Prolonged use may increase intraocular pressure or cause cataracts. Potential eighth cranial nerve toxicity (ototoxicity) with otic use. Do not inject solution subconjunctivally.
What can be used instead?
Other Canadian products sharing ATC code S03CA06 BETAMETHASONE AND ANTIINFECTIVES. 0 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BETAMYCIN OPHTHALMIC/OTIC SOLUTION | 3 MG | SOLUTION | STERIMAX INC | CANCELLED PRE MARKET | DIN 02247446 |
| DOM-GENTAMICIN-BETAMETHASONE | 1 MG | LIQUID | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02238818 |
| PMS-GENTAMICIN-BETAMETHASONE | 3 MG | LIQUID | PHARMASCIENCE INC | CANCELLED PRE MARKET | DIN 02238819 |
| SANDOZ PENTASONE | 3 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | DIN 02244999 |
Who else supplies BETAMETHASONE AND ANTIINFECTIVES worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BETAMETHASONE AND ANTIINFECTIVES appears in 2437 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.